Wed, Oct 1, 2014, 7:52 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Generex Biotechnology Corp. Message Board

eye4profit1 6 posts  |  Last Activity: Sep 9, 2014 5:21 PM Member since: May 21, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • It's looking more like it folks! Galena is struggling big time to complete enrollment. How many times they pushed back enrollment completion to date? Now they say early 2015 after they touted end of 2014 for several months. Can you say misleading investors? Do you think market is not closely watching the nonsense these folks tout at their Quarterly conferences? They wasted 2012 sitting on their sorry #$%$ and only commenced enrollment after signing on with LEICA. Now, they have provided shots a tremendous ammunition against the company. At this point, all signs points to a serious PP decline till at least after Mar 2015 (if that is not pushed back again).. Not looking good in the least. No catalyst in the short term; GALE-401 PR today is just a fluff. Do not bet on Zuplenz to prop the PP in January. I doubt the market is buying the Zuplenz nonsense. IMO.

    What are the chances that Neuvax/Herceptin enrollment is also struggling and Gale management decided to keep it quiet on that front as well? Are they even half way through the projected 300 enrollment? I SERIOUSLY DOUBT IT! As much as I hate to admit, I may have to start paying attention to what AF says about GALE management. I think there is some truth in his assertions about the company.

    Sentiment: Hold

  • Now changed by Galena from June 2015 to June 2017 for a trail that officially started in Jan 2012. For me, this is the first time I would see an Ph3 trial primary completion date lasting 5 years from start date. 3yrs is the gold standard. Does it explain why institutions started bailing out the door from 29% to 19%?

    Last year, institutions were loading up just as retail holders in the expectation then of primary completion date of June 2015 as indicated. IMO, this push back no doubt vindicated AF assertion that Galena management hid from its shareholders the fact that PRESENT trial was struggling enrolling patients.

    If GALENA "GO" it alone without partnership, between now and June 2017, how many dilutions are we to expect? That there would be an offering in 11/2014 and NLT 1/2015 is not in doubt now or is it? I can smell it right after announcement of completion of enrolment for Neuvax PRESENT trial.

    Sentiment: Hold

  • Reply to

    Roche Group

    by kivkovich Aug 14, 2014 3:36 PM
    eye4profit1 eye4profit1 Aug 14, 2014 7:44 PM Flag

    When will you blind followers wake up and smell the coffee? I am a GALE long just as you (if you are), however, keep it real with Galena management. There is a reason Galena management has been DEAD SILENT on the progress, (if any) of the Herceptin/Neuvax trial. Ask yourself, when was the last time you heard management informed shareholders on the status/number of patients enrolled to date? The trials calls for 300 patients 150/150. There is reason you heard in the last CC that enrolment completion will be no earlier than late 2015. However, given Galena management's record on the never ending "COMPLETION OF ENROLMENT FOR P3 PRESENT TRIAL (a trial that started in 2012), you can bet that same pattern of several "push backs" will hold through for Herceptin/Neuvax combo trial. Do not be shocked if enrolment struggles to complete even in 2016. Again, Galena management is silent on the issue for a reason. If the trial enrolment is proceeding well, Galena management will be the first out there pumping the fact. Right here and now though, fact remains the reverse is the case. Just my 2cent observation! Here is the schedule from for N/H trial:

    Estimated Enrollment: 300
    Study Start Date: January 2013
    Estimated Study Completion Date: December 2017
    Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)

    Here is the schedule for the PRESENT TRIAL:
    Estimated Enrollment: 700
    Study Start Date: November 2011
    Estimated Study Completion Date: June 2024
    Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)

    Take note that Galena updated the site AUGUST 2014. What changed? The PRIMARY COMPLETION DATE from MAY 2015 to JUNE 2017. That should tell you something. A serious pushback due to trial enrolment struggle. If you think about it, AF was right after all.

    Sentiment: Hold

  • I'm a long and have been since May 2012. Needless, I could not believe the extent of the gibberish, stuttering, absolute lack of confidence and just overall ineptness of the entire gathering. These folks even went as far as contradicting one another in the same CC. Then series of bad news woven together for an "F" minus. Herceptin/Neuvax enrolment to complete late 2015? Gastric Cancer in India will now initiate in 2015 as opposed to 2014 as stated and when exactly in 2015? Neuvax interim now late 2015? Are we being told the truth here or we just being strung along? Maybe, just maybe AF was right when he stated that GALE was/is experiencing problems enrolling patients for Neuvax. The same enrolment Galena projected to complete in late 2013; later pushed to early 2014 and now pumped to complete by YE 2014? I don't know what to believe anymore. If Abstral is struggling and appear is losing thrust in sales, what then are we to expect from Zuplenz sales? Can anyone smell dilution knocking on the door? At current burn rate, how far will $39 million take the company before it is compelled to dilute considering lag in Abstral sales and potential slow Zuplenz sales next year upon take off?

    For the 1st time ever, my confidence in this management has seriously eroded. I still believe in the science behind Neuvax but will nevertheless reevaluate my holding strategy. Absolutely mystifying to listen to a director who couldn't pronounce name of his company's product correctly. Are you kidding me? Throughout the CC, the entire team sound disoriented, depressed and lacking any positive aura. I was left with a sense that the CC was all about damage control. A price would be paid for this humongous failure in performance and I WILL BE SHOCKED IF THE PPS DO NOT HIT $1.50 and deservedly so.

    More importantly, is Galena due for serious management shake up? 22 million shares shorted says a lot about Wall Street confidence in Galena management.

    Sentiment: Hold

  • Reply to

    Werbowksky v. Hillsberg et al

    by fugitive6129 Aug 6, 2014 6:30 PM
    eye4profit1 eye4profit1 Aug 10, 2014 9:57 AM Flag

    Are you sure that what you wrote explains FULLY what a "Motion to Withdraw" consist of? It is astonishing how the internet allow low IQ variants to pose as though they are bright and all that.

    Sentiment: Strong Buy

  • eye4profit1 eye4profit1 Jul 22, 2014 9:48 PM Flag

    $150 per share? Upon approval? Sometimes I shake my head when you and danindenver33 post ridiculous valuations for GALE. PBYI just announced p3 combination trial result with Herceptin and have yet to get FDA approval, yet the stock soared to $179 AH and could increase dramatically tomorrow. ICPT upon announcing interim,saw its stock price shoot to $490+ from $76 in 3 days. GALE E75 PRESENT is a "Stand Alone" treatment. Can anyone imaging how astronomical the valuation gets if interim is excellent? ICPT will be a child's play IMO. Then add the icing on the cake with Neuvax/Herceptin combo trial which is the equivalent trial of what PBYI just posted. All these still not factoring GALE 301, GALE 401, prospective initiation of gastric cancer trials in India this year with Neuvax. Note that I did not even mention Abstral and Zuplenz. The moment Neuvax post excellent interim result, this baby will fly beyond all speculators projections.

    Ask yourself this: did anyone EVER projected before interim that ICPT will go to $490+? Did anyone projected PBYI to hit $179 today?

    Sentiment: Strong Buy

0.021+0.002(+11.70%)Oct 1 3:58 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.